GO
Loading...

Enter multiple symbols separated by commas

Amgen Inc

More

  • *Euro gains on Greece optimism. NEW YORK, April 27- Wall Street fell modestly on Monday following healthcare stocks, but European shares and the euro advanced on optimism over talks between Greece and its lenders after Greece reshuffled its negotiating team. Concerns over Greece have mounted since the country looks set to run out of cash in coming weeks.

  • Midday Glance: Biotechnology companies Monday, 27 Apr 2015 | 1:50 PM ET

    Amgen Inc. fell $5.07 or 3.0 percent, to $162.84. Biogen Idec fell $11.37 or 2.8 percent, to $390.34. Celgene Corp. fell $3.51 or 3.0 percent, to $115.20.

  • *Amgen's fall drags downs biotech stocks. April 27- U.S. stocks reversed course to move lower in early afternoon trading on Monday as healthcare stocks led by Amgen dragged on the three major indexes. The S&P Healthcare index was down 1.32 percent, with Amgen's 3 percent drop to $163.02 the biggest drag on both the S&P 500 and the Nasdaq.

  • Early Glance: Biotechnology companies Monday, 27 Apr 2015 | 11:25 AM ET

    Amgen Inc. fell $1.08 or. 6 percent, to $166.83. Biogen Idec fell $1.10 or. 3 percent, to $400.62. Celgene Corp. fell$. 50 or. 4 percent, to $118.21.

  • *FDA cites concerns over late-stage study design, results. April 27- U.S. Food and Drug Administration staff reviewers said an accelerated review of drugmaker Amgen Inc's skin cancer immunotherapy cannot be considered at this time, citing concerns over the design and results of a key study. T-Vec represents a new class of agent for the treatment of metastatic...

  • April 27- The U.S. Food and Drug Administration should not consider an accelerated review of Amgen Inc's marketing application for its skin cancer vaccine, FDA staff reviewers concluded in documents released on Monday, citing concerns over the design and results of a key study. The review comes two days before a panel of FDA advisers votes on whether the...

  • April 27- The U.S. Food and Drug Administration should not consider an accelerated review for drugmaker Amgen Inc's marketing application for its skin cancer vaccine, FDA staff reviewers concluded in documents released on Monday. The review comes two days before a panel of FDA advisers votes on whether the treatment, a cancer-killing virus called talimogene...

  • Final Glance: Biotechnology companies Friday, 24 Apr 2015 | 8:08 PM ET

    Amgen Inc. fell $1.26 or. 7 percent, to $167.91. Biogen Idec fell $28.57 or 6.6 percent, to $401.71. Celgene Corp. rose $2.62 or 2.3 percent, to $118.71.

  • Midday Glance: Biotechnology companies Friday, 24 Apr 2015 | 1:36 PM ET

    Amgen Inc. fell $1.01 or. 6 percent, to $168.16. Biogen Idec fell $25.40 or 5.9 percent, to $404.88. Celgene Corp. rose $3.05 or 2.6 percent, to $119.14.

  • Early Glance: Biotechnology companies Friday, 24 Apr 2015 | 10:55 AM ET

    Amgen Inc. fell $1.09 or. 6 percent, to $168.08. Biogen Idec fell $26.23 or 6.1 percent, to $404.05. Celgene Corp. rose$. 79 or. 7 percent, to $116.88.

  • Final Glance: Biotechnology companies Thursday, 23 Apr 2015 | 6:05 PM ET

    Amgen Inc. rose$. 07 or percent, to $169.17. Biogen Idec rose $6.71 or 1.6 percent, to $430.28. Celgene Corp. rose$. 55 or. 5 percent, to $116.09.

  • April 24- Fifteen years and 31 trading days. A lot has changed- Apple Inc, now the most highly valued U.S. public company, had a meager $4.49 share price and certainly was not on Wall Street's hot list. Nasdaq value April 23 2015 March 2000 $8.2 trillion $6.6 trillion Nasdaq P/E April 2015 March 2000.

  • Midday Glance: Biotechnology companies Thursday, 23 Apr 2015 | 1:24 PM ET

    Amgen Inc. fell$. 81 or. 5 percent, to $168.29. Biogen Idec rose $5.95 or 1.4 percent, to $429.52. Celgene Corp. rose$. 39 or. 3 percent, to $115.93.

  • Early Glance: Biotechnology companies Thursday, 23 Apr 2015 | 11:02 AM ET

    Amgen Inc. fell $1.85 or 1.1 percent, to $167.25. Biogen Idec fell $1.23 or. 3 percent, to $422.34. Celgene Corp. fell$. 19 or. 2 percent, to $115.35.

  • That has focused attention on other AbbVie drugs with blockbuster potential, including Viekira Pak, a new hepatitis C medication approved in the U.S. in December. But U.S. sales of $138 million in the first quarter came in below expectations of $215 million, on average, according to survey figures cited by analyst Robyn Karnauskas of Deutsche Bank.

  • Final Glance: Biotechnology companies Wednesday, 22 Apr 2015 | 6:13 PM ET

    Amgen Inc. rose$. 64 or. 4 percent, to $169.10. Biogen Idec rose $1.46 or. 3 percent, to $423.57. Celgene Corp. rose$. 72 or. 6 percent, to $115.54.

  • Midday Glance: Biotechnology companies Wednesday, 22 Apr 2015 | 1:39 PM ET

    Amgen Inc. rose$. 63 or. 4 percent, to $169.09. Biogen Idec fell $1.52 or. 4 percent, to $420.59. Celgene Corp. rose$. 36 or. 3 percent, to $115.18.

  • Early Glance: Biotechnology companies Wednesday, 22 Apr 2015 | 10:25 AM ET

    Amgen Inc. rose$. 66 or. 4 percent, to $169.12. Biogen Idec rose $2.39 or. 6 percent, to $424.50. Celgene Corp. rose $1.08 or. 9 percent, to $115.90.

  • Early movers: BA, KO, TMO, NLSN, AN & more Wednesday, 22 Apr 2015 | 7:58 AM ET
    Traders work the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • April 21- Amgen Inc reported higher first-quarter earnings on Tuesday, helped by price increases for its best-selling drugs, as well as lower spending on research and development. Amgen shares, which rose 1.5 percent in regular trading, were up another 2.3 percent at $172.25 after hours. He added, however, that overall cost trims are on track, and Amgen raised its...